Warfarin INR Review Worksheet

About the Warfarin INR Review Worksheet

This warfarin worksheet compares a current INR with the target range used for the selected indication and shows the kind of weekly-dose arithmetic many anticoagulation services review when a result is slightly below or above range. It is meant for dose-review conversations and cross-checking, not for self-adjusting anticoagulation at home.

Warfarin has a narrow therapeutic window, and dose requirements vary widely between patients. Age, liver function, diet, acute illness, missed doses, and interacting medicines can all shift the INR. Genetic factors such as CYP2C9 and VKORC1 also help explain why two patients with the same indication may need very different weekly totals.

Because of that variability, the useful question is usually not "What is the right milligram number?" but "How far from range is the INR, what changed recently, and is simple weekly-dose math still reasonable?" This page keeps the target range, weekly total, interaction list, and tablet strengths in one place so the calculation can be reviewed in context.

When This Page Helps

Warfarin follow-up usually hinges on the weekly total, the target range, recent interacting changes, and whether the result is only slightly out of range or clearly concerning. Keeping those pieces together makes it easier to review the math without pretending the page can replace an anticoagulation service or clinician.

How to Use the Inputs

1. Choose the anticoagulation indication or enter a custom INR range.
2. Enter the current daily dose, weekly total, and most recent INR.
3. Enter age if you want the simplified bleeding-context flag.
4. Review whether the INR is below, in, or above the target range.
5. Use the weekly-dose output as rough worksheet math when the INR is only mildly out of range.
6. When the INR is markedly elevated, treat the page as a prompt for clinician review rather than a dosing answer.
7. Use the interaction and tablet-strength tables as supporting reference material during follow-up review.

Example Calculation

Tips & Best Practices

• Think in terms of total weekly milligrams first; daily tablet schedules are just a way to distribute that weekly total.
• When the INR is unexpectedly off, review missed doses, new medicines, illness, alcohol intake, and diet changes before trusting any percentage adjustment.
• Many clinics keep single-step changes modest when the INR is only a little out of range.
• Use the interaction table as a review prompt, not a complete medication-safety screen.
• Markedly elevated INRs need individualized review rather than routine worksheet math.
• Document the actual weekly schedule clearly if alternating tablet strengths are used across the week.

Pharmacogenomic and Clinical Variability

Warfarin dose requirements can vary several-fold between patients. CYP2C9 affects metabolism, VKORC1 affects sensitivity, and everyday clinical issues such as illness, liver function, alcohol intake, missed doses, and changing vitamin K intake often matter just as much in routine follow-up. That is why a patient with the same indication and a similar INR may still need a very different long-term weekly dose than someone else.

Why Weekly Totals Matter More Than Single Tablets

Most review workflows think in total weekly milligrams rather than one tablet strength per day. Weekly totals allow smaller adjustments by alternating strengths across the week, which is often more realistic than trying to force every day to look identical. This page therefore keeps the weekly total, daily average, and nearest tablet strength in the same place.

When Simple Dose Math Stops Being Useful

Small INR deviations often invite rough percentage math, but that approach weakens once the INR is markedly elevated or the patient has bleeding symptoms, major interacting changes, or peri-procedural considerations. In those settings, the more important question is not the next arithmetic step but whether the overall situation still fits routine outpatient follow-up or needs more urgent individualized review.

Frequently Asked Questions

• What is the common INR target for atrial fibrillation?

  Atrial fibrillation is commonly managed to an INR range of 2.0–3.0. That range is used as the reference context on this page, but the treating clinician or anticoagulation service should confirm the actual goal for a specific patient.

• How often is INR usually rechecked?

  Follow-up timing depends on how stable the INR has been, whether a dose change was made, and whether a new interaction or illness is in play. Stable long-term patients may be reviewed at wider intervals, while out-of-range results often prompt much sooner follow-up.

• What foods affect warfarin?

  Foods rich in vitamin K can lower the INR if intake changes meaningfully from the usual pattern. The practical issue is consistency: large swings in vitamin K intake make INR interpretation harder than a steady diet does.

• Why does the worksheet stop giving a routine dose estimate when INR is very high?

  Once the INR is markedly elevated, the safe next step depends on more than percentage math. Bleeding symptoms, recent medication changes, liver function, falls, procedures, and local anticoagulation pathways matter, so the page shifts to review-context wording instead of pretending a single weekly number is enough.

• Can different warfarin brands or manufacturers matter?

  They are usually close enough for most patients, but any manufacturer change is still worth noting when an INR trend stops making sense. A review after the switch is more useful than assuming the product change could never matter.

• How is warfarin different from DOACs?

  Direct oral anticoagulants such as apixaban, rivaroxaban, dabigatran, and edoxaban generally do not require INR monitoring and have fewer food interactions. Warfarin still remains relevant for some mechanical valves, certain thrombophilia scenarios, and settings where cost or other factors matter.